Compare McKesson Corporation (MCK) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Toronto-Dominion Bank — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Toronto-Dominion Bank trades at $120.7 (market cap $197.03B). The key difference: Toronto-Dominion Bank is far larger — about 2× McKesson Corporation's market cap, and Toronto-Dominion Bank pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| MCK | TD | |
|---|---|---|
Market Cap | $97.35B | $197.03B |
Sector | Health | Financials |
52-Week High | $995.69 | $124.80 |
52-Week Low | $659.01 | $72.55 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
TD stock trades at $120.56, down 2.46% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.74 exceeding the $1.63 estimate. Revenue growth remains steady, increasing from $56.3B in 2024 to $61.3B in 2025, while net income margin improved significantly to 33.51%.
Analyst consensus is bullish with a $153 price target representing 27% upside potential. Key risks include volatile cash flow patterns and high debt levels, while opportunities lie in continued earnings outperformance and dividend stability. The stock presents a compelling value proposition for investors seeking banking sector exposure with growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
